[1] 陆伦根. 胆汁淤积性肝病管理指南(2021)[J].中华内科杂志,2021,60(12):1075-1087.
[2] Cancado E L, Leitao R M, Carrilho F J, et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase[J]. Am J Gastroenterol, 1998,93(9):1510-1517.
[3] Folvik G, Hilde O, Helge G O. Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases[J]. Scand J Gastroenterol,2012,47(4):482-488.
[4] Mizuochi T, Kimura A, Tanaka A, et al. Characterization of urinary bile acids in a pediatric BRIC-1 patient: effect of rifampicin treatment[J]. Clin Chim Acta, 2012,413(15-16):1301-1304.
[5] Salyani A, Barasa L, Rajula A,et al. Benign recurrent intrahepatic cholestasis (BRIC): an african case report[J]. Case Rep Gastrointest Med,2020,2020:2894293.
[6] Sohn M J, Woo M H, Seong M W, et al. Benign recurrent intrahepatic holestasis type 2 in siblings with novel ABCB11 mutations[J]. Pediatr Gastroenterol Hepatol Nutr,2019,22(2):201-206.
[7] Ellis E, Wagner M, Lammert F, et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin[J]. J Hepatol,2006,44(1): 243-245.
[8] Ozturk K, Demirci H, Sakin Y S, et al. Efficiency of rifampicin in emergency treatment of severe hyperbilirubinemia : report of two cases and review of literature[J]. Acta Gastroenterol Belg,2015,78(2):256-258.
[9] Dijk R V, Kremer A E, Smit W, et al. Characterization and treatment of persistent hepatocellular secretory failure[J]. Liver Int,2015,35(4):1478-1488.
[10] Shi M, Sheng L, Lian M, et al. Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure[J]. J Gastroenterol Hepatol, 2021,36(11):3233-3238.
[11] 白欢欢,冯惠君,郭立杰,等.单纯淤胆型药物性肝损伤临床生化及病理特点分析[J]. 肝脏,2024,29(1):37-40.
[12] 俞楼,陆伦根. 遗传性胆汁淤积性肝病的研究进展[J]. 肝脏, 2022, 27(8):844-846.
[13] 何睿,张才江,孔维金,等. 进行性家族性肝内胆汁淤积症常见类型的发病机制及治疗进展[J].肝脏,2023,28(8):994-997.
[14] Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury[J]. Pharmacogenet Genomics, 2007,17(1): 47-60.
[15] 邓玉婷,魏民华,周俊英. Gilbert综合征研究进展[J].实用肝脏病杂志,2021,24(2):156-159.
[16] 王铭杰,陈立.药物性胆汁淤积的诊治进展[J]. 临床内科杂志,2021,38(7):445-448.
[17] 徐永吉,李文楷,刘杰,等.利福平对小鼠的肝毒性及胆酸代谢基因的影响[J].中国药理学通报, 2016,32(6):841-845.
[18] 张刚,陈磊,陈静,等.不同剂量利福平致小鼠肝损伤特点的研究[J].局解手术学杂志,2017,26(4):244-247.
[19] Webb G J,Rahman S R,Levy C,et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study[J].Aliment Pharmacol Ther,2018,47(8): 1213-1219.
[20] Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis[J]. Gastroenterology, 1992, 102(6): 2077-2080.
[21] Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials[J]. Liver Int, 2006, 26(8):943-948.
[22] 刘腾,王建设.遗传性胆汁淤积症诊疗[J].中华肝脏病杂志, 2023,31(9):901-904. |
